Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force.
The International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the National Institutes of Health on September 30, 2010 to address development and application of biomarkers in cancer immunotherapy. The symposium, titled Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Task Force, gathered approximately 230 investigators equally from academia, industry and governmental/regulatory agencies from around the globe for panel discussions and presentations on the following topics: 1) immunologic monitoring: standardization and validation of assays; 2) correlation of immunity to biologic activity, clinical response and potency assays; 3) novel methodologies for assessing the immune landscape: clinical utility of novel technologies; and 4) recommendations on incorporation of biomarkers into the clinical arena. The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website.
Departments of Medicine, Surgery and Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Lisa H
LH
Butterfield
Mary L
ML
Disis
Samir N
SN
Khleif
James M
JM
Balwit
Francesco M
FM
Marincola
D026683:Advisory Committees; D000818:Animals; D014408:Biomarkers, Tumor / Q000276:immunology*; D002986:Clinical Trials as Topic; D006287:Health Planning Guidelines; D006801:Humans; D007109:Immunity / Q000276:immunology; D007118:Immunoassay; D007167:Immunotherapy; D051379:Mice; D015166:Monitoring, Immunologic; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D012015:Reference Standards; D015203:Reproducibility of Results; D012955:Societies, Medical
D014408:Biomarkers, Tumor